Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Change in Accured Expenses (2016 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Change in Accured Expenses for 11 consecutive years, with -$619376.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 33.69% year-over-year to -$619376.0, compared with a TTM value of -$210526.0 through Dec 2025, down 394.42%, and an annual FY2025 reading of -$54442.0, down 435.77% over the prior year.
  • Change in Accured Expenses was -$619376.0 for Q4 2025 at Neuroone Medical Technologies, down from $302463.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.7 million in Q3 2022 and bottomed at -$1.4 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is -$28344.6, with a median of $53193.5 recorded in 2025.
  • The sharpest move saw Change in Accured Expenses skyrocketed 1227.97% in 2022, then tumbled 7447.94% in 2023.
  • Year by year, Change in Accured Expenses stood at -$317456.0 in 2021, then rose by 3.57% to -$306125.0 in 2022, then plummeted by 69.4% to -$518584.0 in 2023, then increased by 10.66% to -$463292.0 in 2024, then crashed by 33.69% to -$619376.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for NMTC at -$619376.0 in Q4 2025, $302463.0 in Q3 2025, and $73839.0 in Q2 2025.